Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PEPD | P12955 | 2/20 | 0.53 |
| ▸ | XPNPEP1 | Q9NQW7 | 1/20 | 0.53 |
| ▸ | MMP2 | P08253 | 7/20 | 0.47 |
| ▸ | ANPEP | P15144 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 4/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29724334 | 1.00 | PEPD (0.53) | PEPDXPNPEP1MMP2ANPEPALDH1A1 | |
| SCHEMBL14060300 | 1.00 | PEPD (0.53) | PEPDXPNPEP1MMP2ANPEPALDH1A1 | |
| SCHEMBL3789843 | 0.86 | MMP2 (0.65) | PEPDXPNPEP1MMP2ANPEPALDH1A1 | |
| SCHEMBL3785989 | 0.86 | MMP2 (0.65) | PEPDXPNPEP1MMP2ANPEPALDH1A1 | |
| SCHEMBL3780617 | 0.86 | MMP2 (0.65) | PEPDXPNPEP1MMP2ANPEPALDH1A1 | |
| SCHEMBL3782725 | 0.86 | MMP2 (0.65) | PEPDXPNPEP1MMP2ANPEPALDH1A1 | |
| SCHEMBL27230349 | 0.82 | PEPD (0.42) | PEPDXPNPEP1MMP2ANPEPPIN1 | |
| SCHEMBL30686137 | 0.81 | MMP2 (0.47) | PEPDMMP2ANPEPALDH1A1POLB | |
| SCHEMBL318353 | 0.81 | MMP2 (0.47) | PEPDMMP2ANPEPALDH1A1POLB | |
| SCHEMBL3785722 | 0.80 | PEPD (0.52) | PEPDXPNPEP1MMP2ANPEPALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240327402-A1 | PYRIMIDINE OR PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF IN PHARMACY | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2024-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240327402-A1 | PYRIMIDINE OR PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF IN PHARMACY | WEE1, WEE2, EGFR | PEPD 930/4885XPNPEP1 801/4885MMP2 4185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.